A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer.

IF 3.1 Q2 ONCOLOGY
Oncology Reviews Pub Date : 2025-02-12 eCollection Date: 2025-01-01 DOI:10.3389/or.2025.1516409
Amir Mahdi Khamaneh, Davoud Jafari-Gharabaghlou, Khalil Ansarin, Pouya Pazooki, Zahra Akbarpour, Behrooz Naghili, Nosratollah Zarghami
{"title":"A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer.","authors":"Amir Mahdi Khamaneh, Davoud Jafari-Gharabaghlou, Khalil Ansarin, Pouya Pazooki, Zahra Akbarpour, Behrooz Naghili, Nosratollah Zarghami","doi":"10.3389/or.2025.1516409","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is the most prevalent neoplasm in women. ER<sup>+</sup> (Luminal subtype), representing over 70% of breast tumors, is a genetically diverse group. Structural and Numerical-Chromosomal instability initiates tumor development and is recognized as the primary driver of genetic alteration in luminal breast tumors. Genomic instability refers to the increased tendency of cancer cells to accumulate genomic alterations during cell proliferation. The cell cycle check-point response to constant and stable genomic alterations in tumor cells drives this process. The impact of CNV patterns and aneuploidies in cell cycle and proliferation perturbation has recently been highlighted by scientists in Luminal breast tumors. The impact of chromosomal instability on cancer therapy and prognosis is not a new concept. Still, the degree of emerging genomic instability leads to prognosis alteration following cell cycle deregulation by chromosomal instability could be predicted by CNVs-based reclassification of breast tumors. In this review, we try to explain the effect of CIN in the cell cycle that ended with genomic instability and altered prognosis and the impact of CIN in decision-making for a therapy strategy for patients with luminal breast cancer.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1516409"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861078/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/or.2025.1516409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer is the most prevalent neoplasm in women. ER+ (Luminal subtype), representing over 70% of breast tumors, is a genetically diverse group. Structural and Numerical-Chromosomal instability initiates tumor development and is recognized as the primary driver of genetic alteration in luminal breast tumors. Genomic instability refers to the increased tendency of cancer cells to accumulate genomic alterations during cell proliferation. The cell cycle check-point response to constant and stable genomic alterations in tumor cells drives this process. The impact of CNV patterns and aneuploidies in cell cycle and proliferation perturbation has recently been highlighted by scientists in Luminal breast tumors. The impact of chromosomal instability on cancer therapy and prognosis is not a new concept. Still, the degree of emerging genomic instability leads to prognosis alteration following cell cycle deregulation by chromosomal instability could be predicted by CNVs-based reclassification of breast tumors. In this review, we try to explain the effect of CIN in the cell cycle that ended with genomic instability and altered prognosis and the impact of CIN in decision-making for a therapy strategy for patients with luminal breast cancer.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Reviews
Oncology Reviews ONCOLOGY-
CiteScore
6.30
自引率
0.00%
发文量
9
审稿时长
9 weeks
期刊介绍: Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信